Finance

Lists
Why is KYTX down 5.86%?
Dive Deeper
KYTX:NASDAQ
Kyverna Therapeutics Inc
$ 7.07
-5.86%
(-0.44) 1D
$ 7.07
0.00% (0.00)
After hours
Closed: 9-р сарын 23, 16:00:01 (GMT-4)  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KYTX...
Open
$ 7.50
High
$ 7.54
Low
$ 6.99
Mkt. cap
437.23 сая
Avg. vol.
750.26 мян
Volume
1.03 сая
52-wk high
$ 13.67
52-wk low
$ 5.30
EPS
-$ 2.94
Shares outstanding
61.84 сая
No. of employees
149
Open
$ 7.50
High
$ 7.54
Low
$ 6.99
Mkt. cap
437.23 сая
Avg. vol.
750.26 мян
Volume
1.03 сая
52-wk high
$ 13.67
52-wk low
$ 5.30
EPS
-$ 2.94
Shares outstanding
61.84 сая
No. of employees
149
About Kyverna Therapeutics Inc
CEO-
Employees149
Founded2018
HeadquartersEmeryville, Калифорни, Америкийн Нэгдсэн Улс
Sector-
Websitekyvernatx.com
Analyst ratings
Based on 4 analysts giving stock ratings to KYTX in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for KYTX in the last 3 months.
Highest
Current $ 7.07
$ 33.00 (+366.76%)
Average
$ 30.33 (+329.00%)
Lowest
$ 25.00 (+253.61%)
Analyst
Recommendation
Action
Price target
Projected
Date
Derek Archila
Wells Fargo
Buy
Maintained
$ 33.00
+366.8%
09/01/2026
Michael Ulz
Morgan Stanley
Buy
Reiterated
$ 33.00
+366.8%
08/12/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$ 25.00
+253.6%
08/12/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
08/12/2026
Brian Cheng
J.P. Morgan
Buy
Reiterated
$ 29.00
+310.2%
05/13/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
$ 30.00
+324.3%
03/30/2026
Last report
2026 оны 8-р сарын 11
Fiscal period
Q2 2026
EPS / Est. (USD)
-$ 0.63 / -$ 0.68
+7.28%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025 оны 9-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
-
-
-
-
Cost of goods sold
30.46 сая
-103.71 сая
30.07 сая
-
Cost of revenue
30.46 сая
-103.71 сая
30.07 сая
-
Research and development expenses
-
133.72 сая
-
24.79 сая
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.27 сая
9.27 сая
11.29 сая
14.77 сая
Operating expense
8.27 сая
142.99 сая
11.29 сая
39.56 сая
Total operating expenses
38.73 сая
39.28 сая
41.37 сая
39.56 сая
Operating income
-38.73 сая
-39.28 сая
-41.37 сая
-39.56 сая
Other non operating income
-53.00 мян
17.00 мян
-21.00 мян
-18.00 мян
EBT including unusual items
-36.79 сая
-37.80 сая
-39.73 сая
-38.32 сая
EBT excluding unusual items
-36.79 сая
-37.80 сая
-39.73 сая
-38.32 сая
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-36.79 сая
-37.80 сая
-39.73 сая
-38.32 сая
Net profit margin
-
-
-
-
Earnings per share
-0.85
-0.80
-0.66
-0.63
Interest and investment income
2.00 сая
1.90 сая
2.33 сая
1.93 сая
Interest expense
-7.00 мян
-444.00 мян
-667.00 мян
-674.00 мян
Net interest expenses
1.99 сая
1.46 сая
1.66 сая
1.26 сая
Depreciation and amortization charges
-
-
-
-
EBITDA
-37.84 сая
-38.91 сая
-41.02 сая
-39.12 сая
Gain or loss from assets sale
40.00 мян
20.00 мян
-
-47.00 мян
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google аппс